VisMederi Group

VisMederi Group is a research and qualified services company group operating in the field of Life Sciences and Public Health.

[VisMederi Group @VisMederi]

Nel nuovo articolo su InsideOver del Prof. Emanuele Montomoli, “Lo spillover acquatico del virus marino Cmnv”, emerge uno scenario poco esplorato: il possibile passaggio all’uomo di un virus tipico degli ecosistemi acquatici.

https://t.co/6q9aVV12xl

#Vismederigroup

[VisMederi Group @VisMederi]

A new article by Prof. Emanuele Montomoli on Insidover highlights a critical yet often overlooked aspect of global events: the health risks associated with mass gatherings.

https://t.co/e2zy5bRras

[VisMederi Group @VisMederi]

VisMederi is a partner in the EU-selected NOFLU consortium supporting early clinical development of a next-generation pandemic influenza vaccine
https://t.co/p7VdLER2QD

#VisMederiGroup

[VisMederi Group @VisMederi]

Brazil eliminates vertical HIV transmission as a public health problem: lessons from a successful prevention model.

https://t.co/gi4FxBwdt6

#GlobalHealth #PublicHealth #Prevention #HealthGeopolitics #Research #VisMederi #InsideOver #SalutePubblica #Prevenzione #Montomoli

[VisMederi Group @VisMederi]

VisMederi America: a new chapter in the Group’s international growth
https://t.co/B44sNKFYRT

#VisMederi #VisMederiAmerica #VisMederigroup #Biotech #Vaccines #Research #USExpansion #LifeSciences #publichealth

[ISRV @isrv_global]

Thank you to our major supporters and sponsors: @CEPIvaccines, @TFGH, @AstraZeneca, @sanofi, @CSL, @pfizer and @VisMederi, whose contributions make #COP2025 possible

[VisMederi Group @VisMederi]

Once again this year, VisMederi features in the “Leader of Growth 2026” ranking by Il Sole 24 Ore and Statista, among the Italian companies showing outstanding performance in terms of growth and development.

👉 Read the full news on our website: https://t.co/BT6Lrm7B0P

[VisMederi Group @VisMederi]

The PEDVAC-iNTS project focuses on advancing the clinical development of a vaccine against non-typhoidal salmonellosis for infants in sub-Saharan Africa, addressing a neglected, poverty-related infectious disease
https://t.co/aGd3CbiZcm
#VisMederi

[VisMederi Group @VisMederi]

È uscito oggi su InsideOver un approfondimento firmato da Emanuele Montomoli dal titolo “La tecnologia a mRNA: come funziona il nuovo pilastro della medicina preventiva.”

https://t.co/YNGBxOF8m7

@E_Montomoli @insideoverita #VisMederigroup #MedicinaPreventiva #Innovazione

[VisMederi Group @VisMederi]

Dalla morte nera medievale al colera dell’Ottocento, fino alle sfide di Covid-19, influenza e Monkeypox nel presente, i pellegrinaggi di massa sono stati spesso accompagnati dall’ombra del contagio.

https://t.co/jgoVZl4rL9

#VisMederi #Pandemie #geopolitica

[VisMederi Group @VisMederi]

L'importanza della diagnostica nella lotta contro il cancro.

L'articolo a cura di Sara Pugliese su InsideOver
https://t.co/K5wWImqLNI

@insideoverita #diagnostica #VisMederi

[VisMederi Group @VisMederi]

Emanuele Montomoli (CSO & Founder) and Alessandro Manenti (CDO) are co-authors of a new scientific publication on a Phase II/III clinical study evaluating the immunogenicity, safety, and tolerability of a new SARS-CoV-2 booster vaccine
🔗 https://t.co/PAXcCvWZgD

[VisMederi Group @VisMederi]

VisMederi represented at GVIRF 2025 by our CSO, Emanuele Montomoli. A valuable opportunity to be part of the global dialogue on vaccine research and innovation. 🌍

https://t.co/TBG80AAsvC

#VisMederi #GVIRF2025 #VaccineResearch #GlobalHealth

[VisMederi Group @VisMederi]

Emanuele Montomoli, VisMederi's Chief Scientific Officer highlights the superior efficacy of the high-dose trivalent flu vaccination in protecting seniors from influenza.
👇
https://t.co/wLlh8CiKfC
#VisMederi

[VisMederi Group @VisMederi]

The VisMederi Group wishes you a very Merry Christmas and a prosperous New Year!
At VisMederi, public health is our commitment, and happiness is at the heart of everything we do. Thank you for being part of our journey.

#MerryChristmas #HappyNewYear #VisMederi

[VisMederi Group @VisMederi]

At the 10th IBP BIOSAFETY CONFERENCE , our Unit Manager Adele Boccuto spoke on a crucial topic: "Emerging viral diseases in an era of global change."
As global challenges rise, so does the need for innovative solutions in biosafety.
#EmergingDiseases #Biosafety #VisMederi

[VisMederi Group @VisMederi]

Prof. Emanuele Montomoli, Founder and CSO of VisMederi participated in the 52° Congresso SIM. He discussed "New Frontiers in Vaccinology", addressing recent advancements and their impact on public health. #Vaccinology #PublicHealth #Microbiology #SIM2024 #VisMederi

[VisMederi Group @VisMederi]

VisMederi is prepared to support any research activity and overall vaccine development for the new public health emergency concerning monkeypox.
Read the full article here: https://t.co/TPVgWx3Dg3

#PublicHealth #Monkeypox #VaccineDevelopment #ResearchSupport #vismederi

[VisMederi Group @VisMederi]

VisMederi has been successfully qualified by Qualifyze for conducting activities according to GCLP (Good Clinical Laboratory Practices).

Both our laboratory facilities have achieved the prestigious SILVER rating!
#VisMederi #Qualifyze #GCLP #SilverRating #LaboratoryExcellence

[VisMederi Group @VisMederi]

Emanuele Montomoli (CSO and VisMederi Founder), Alessandro Manenti (CDO), and Silvia Grappi (Project Director) attended the CEPI Centralized Laboratory Network meeting in Rome.

#VisMederi #CEPI #Innovation #StandardizedAssays #FutureOutbreaks #HealthScience #RomeMeeting